At the end of the treatment evaluation, they also looked at progression ... and dexamethasone for transplantation-eligible ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... patients with myeloma and other blood disorders will ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

Affecting approximately 4,500 people annually in the U.S., AL amyloidosis can be associated with blood cancers, particularly multiple myeloma as well as lymphomas or chronic lymphocytic leukemia.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

Doctors use the presence of these symptoms to tell the difference between precancerous and cancerous disease and to guide treatment. Multiple myeloma activates cells that break down bone called ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Receiving the once-weekly KRd56 treatment ...